Open AccessCardiac regeneration by pharmacologically active microcarriers releasing growth factors and/or transporting adipose-derived stem cells
Author(s) -
Monia Savi,
Leonardo Bocchi,
Emanuela Fiumana,
Caterina Frati,
Francesca Bonafè,
Stefano Cavalli,
Paolo Giovanni Morselli,
JeanPierre Karam,
Claudia N. MonteroMenei,
Claudio Marcello Caldarera,
Carlo Guarnieri,
Claudio Muscari,
Donatella Stilli,
Federico Quaini,
Emilio Musso
Publication year - 2014
Publication title -
journal of biological research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.218
H-Index - 6
eISSN - 2284-0230
pISSN - 1826-8838
DOI - 10.4081/jbr.2014.2141
Subject(s) - stem cell , microcarrier , adipose tissue , regeneration (biology) , hepatocyte growth factor , cardiac function curve , microbiology and biotechnology , myocardial infarction , growth factor , biology , medicine , cardiology , cell , heart failure , receptor , genetics
We tested the hypothesis that cardiac regeneration through local delivery of adipose-derived stem cells (ASCs), activation of resident cardiac stem cells via growth factors (GFs) [hepatocyte growth factor (HGF) and insulin-like growth factor 1 (IGF-1):GFs] or both, are improved by pharmacologically active microcarriers (PAMs) interacting with cells/molecules conveyed on their surface. Rats with one-month old myocardial infarction were treated with ASCs, ASCs+PAMs, GF-releasing PAMs, ASCs+GF-releasing PAMs or vehicle. Two weeks later, hemodynamic function and inducibility of ventricular arrhythmias (VAs) were assessed. Eventually, the hearts were subjected to anatomical and immunohistochemical analyses. A significant ASCs engraftment and the largest improvement in cardiac mechanics occurred in ASC+GF-releasing PAM rats which by contrast were more vulnerable to VAs. Thus, PAMs may improve cell/GF-based cardiac regeneration although caution should be paid on the electrophysiological impact of their physical interaction with the myocardium